duloxetine hydrochloride

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Diabetic Neuropathy, Painful

Conditions

Diabetic Neuropathy, Painful

Trial Timeline

Dec 1, 2005 → Apr 1, 2007

NCT ID

NCT00266643

About duloxetine hydrochloride

duloxetine hydrochloride is a approved stage product being developed by Eli Lilly for Diabetic Neuropathy, Painful. The current trial status is completed. This product is registered under clinical trial identifier NCT00266643. Target conditions include Diabetic Neuropathy, Painful.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Neuropathy, Painful were approved

Approved (20) Terminated (3) Active (0)

✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved

✅Anplag(Sarpogrelate) + PlaceboYuhanApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅Duloxetine + Pregabalin + PlaceboShionogiApproved

✅DuloxetineEli LillyApproved

✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

✅Mosapride + domperidoneSumitomo PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00071708	Pre-clinical	Completed	—	—	Major Depressive Disorder
NCT00960986	Approved	Completed	Aug 1, 2009	Apr 1, 2011	Major Depressive Disorder (MDD)
NCT00437125	Approved	Completed	Mar 1, 2007	Jul 1, 2009	Major Depressive Disorder
NCT00266643	Approved	Completed	Dec 1, 2005	Apr 1, 2007	Diabetic Neuropathy, Painful
NCT00583193	Phase 3	UNKNOWN	Dec 1, 2005	Jun 1, 2008	Posttraumatic Stress Disorders
NCT00191594	Phase 3	Completed	Mar 1, 2005	Aug 1, 2006	Major Depressive Disorder
NCT00191061	Approved	Completed	Oct 1, 2004	Jan 1, 2006	Depressive Disorder
NCT00479726	Approved	Completed	Aug 1, 2004	Jan 1, 2005	Major Depressive Disorder
NCT00036309	Phase 3	Completed	May 1, 2002	Jul 1, 2003	Depressive Disorder
NCT00036335	Phase 3	Completed	Mar 1, 2002	Jan 1, 2003	Depression

Competing Products

20 competing products in Diabetic Neuropathy, Painful

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	25
CHF6467 active	Comac Medical	Phase 1/2	22
Ruboxistaurin mesylate	Eli Lilly	Phase 3	40
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	29
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	23
Baricitinib + Placebo	Eli Lilly	Phase 2	35
LY3857210 + Placebo	Eli Lilly	Phase 2	35
UBX1325	Unity Biotechnology	Phase 2	25
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	25
UBX1325	Unity Biotechnology	Phase 1	19
CT-P42 + Eylea	Celltrion	Phase 3	40
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	43
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	43
CS-3150 + placebo	Daiichi Sankyo	Phase 2	35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	35
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	40
DS-5565 + placebo	Daiichi Sankyo	Phase 3	40
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
Beraprost sodium	Astellas Pharma	Pre-clinical	22